SUGP2: A Drug Target / Disease Biomarker (G10147)
SUGP2: A Drug Target / Disease Biomarker
SUGP2, also known as supraglutide, is a drug that is currently being investigated as a potential treatment for type 2 diabetes. It is taken as an injection once a week and works by helping the body to produce more insulin and lower blood sugar levels.
One of the key benefits of SUGP2 is its ability to slow down the progression of type 2 diabetes. Studies have shown that people with type 2 diabetes who take SUGP2 have seen improvements in their blood sugar levels, as well as their overall health and quality of life.
Another potential benefit of SUGP2 is its potential to become a biomarker for the disease. A biomarker is a substance that is produced by the body that can be used as a sign of the presence of a particular disease or condition. Researchers are interested in using biomarkers to detect and monitor the progress of type 2 diabetes, as this could help to improve treatment outcomes.
In addition to its potential as a drug and biomarker, SUGP2 is also being studied for its potential benefits in other conditions. For example, some studies have shown thatSUGP2 may have anti-inflammatory effects, which could make it useful for treating a variety of inflammatory diseases.
Despite the potential benefits of SUGP2, it is still being studied in clinical trials to determine its safety and effectiveness. The most common side effects ofSUGP2 include nausea, vomiting, and diarrhea. In addition, some people may experience injection site reactions, such as redness, swelling, or itching.
Overall, SUGP2 is a drug that is still being investigated as a potential treatment for type 2 diabetes and may have a variety of potential benefits in addition to its use as a drug. As more research is conducted, it is likely that we will gain a better understanding of its potential and how it can be used to improve the lives of people with type 2 diabetes.
Protein Name: SURP And G-patch Domain Containing 2
Functions: May play a role in mRNA splicing
More Common Targets
SUGT1 | SUGT1P1 | SUGT1P2 | SUGT1P3 | SUGT1P4-STRA6LP-CCDC180 | SULF1 | SULF2 | Sulfotransferase | SULT1A1 | SULT1A2 | SULT1A3 | SULT1A4 | SULT1B1 | SULT1C2 | SULT1C3 | SULT1C4 | SULT1C5P | SULT1D1P | SULT1E1 | SULT2A1 | SULT2B1 | SULT4A1 | SULT6B1 | SUMF1 | SUMF2 | SUMO activating enzyme complex | SUMO1 | SUMO1P1 | SUMO1P3 | SUMO2 | SUMO2P21 | SUMO2P3 | SUMO2P6 | SUMO2P8 | SUMO3 | SUMO4 | SUN1 | SUN2 | SUN3 | SUN5 | SUOX | Superoxide dismutase (SOD) | Suppressor of cytokine signaling (SOCS) | SUPT16H | SUPT20H | SUPT20HL1 | SUPT20HL2 | SUPT3H | SUPT4H1 | SUPT5H | SUPT6H | SUPT7L | SUPV3L1 | SURF complex | SURF1 | SURF2 | SURF4 | SURF6 | Survival of motor neuron (SMN) complex | SUSD1 | SUSD2 | SUSD3 | SUSD4 | SUSD5 | SUSD6 | SUV39H1 | SUV39H2 | SUZ12 | SUZ12P1 | SV2A | SV2B | SV2C | SVBP | SVEP1 | SVIL | SVIL-AS1 | SVIL2P | SVIP | SVOP | SVOPL | SWAP complex | SWAP70 | SWI5 | SWI5-SFR1 complex | SWINGN | SWSAP1 | SWT1 | SYAP1 | SYBU | SYCE1 | SYCE1L | SYCE2 | SYCE3 | SYCN | SYCP1 | SYCP2 | SYCP2L | SYCP3 | SYDE1 | SYDE2